Across TCGA pan-cancer cohorts, RNF220 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RNF220 data layer compared with 30 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RNF220 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNF220 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where RNF220 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.686	1.000	<.001	30	view →
LUAD	OS	Tertile	II,III,IV	0.806	0.371	.009	14	view →
GBM	OS	Quartile	All	0.758	0.298	<.001	10	view →
CCRCC	OS	Median	II,III,IV	1.000	0.435	.015	8	view →
PDAC	DFS	Median	III,IV	0.174	0.536	.017	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RNF220 tumor-vs-normal RNA expression · all RNF220 data types